Advertisement

Therapie von vaskulären Hochrisikopatienten: Telmisartan, Ramipril oder eine Kombination?

Therapy of patients at high risk for vascular events, Telmisartan, ramipril or a combination?

  • 67 Accesses

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Literatur

  1. 1.

    Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group (2002) Effect of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360: 752–760

  2. 2.

    Pfeffer MA, McMurray JJV, Velazquez EJ et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators (2003) Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 349: 1893–1906

  3. 3.

    Pitt B, Poole-Wilson PA, Segal R et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – The Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582–1587

  4. 4.

    The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342: 145–153

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin:

Prof. Dr. R. Düsing hat für die Fa. Boehringer Ingelheim honorierte wissenschaftliche Vorträge gehalten.

Author information

Correspondence to Prof. Dr. R. Düsing.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Düsing, R., Nitschmann, S. Therapie von vaskulären Hochrisikopatienten: Telmisartan, Ramipril oder eine Kombination?. Internist 49, 1137–1140 (2008) doi:10.1007/s00108-008-2199-4

Download citation